C D Naylor, S Bronskill, V Goel. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Cost-Benefit AnalysisFibrinolytic Agents/economicsFibrinolytic Agents/therapeutic useHumansMyocardial Infarction/drug therapyPlasminogen Activators/economicsPlasminogen Activators/therapeutic useStreptokinase/economicsStreptokinase/therapeutic useThrombolytic Therapy/economics
Substances: See more » Fibrinolytic AgentsStreptokinasePlasminogen Activators
Year: 1993 PMID: 8221354
Source DB: PubMed Journal: Can J Cardiol ISSN: 0828-282X Impact factor: 5.223